Forehead

Inject 8-20 U botulinum toxin intramuscularly in 4-6 evenly spaced points across the frontalis. Maintain at least 2 cm above the brow to reduce brow ptosis risk. Superficial plane with 30 G needle and conservative aliquots (e.g., 1-2 U) per site improves control in hyperkinetic or low-forehead patients. Avoid filler in the upper third; if used for mild contour adjustment, use very small, superficial micro-aliquots with low pressure and vigilant perfusion checks. ^{1 2 3 4 5}

Glabella

Typical toxin total 15-25 U: corrugator (bilateral) and procerus targeted directly, avoiding medial over-diffusion. Filler is generally discouraged due to ophthalmic anastomoses; if essential, consider a blunt cannula on bone with minute aliquots and slow, low-pressure delivery. Any vascular-compromise signal triggers immediate activation of occlusion and ophthalmology pathways. ^{1 2 3 5 7}

Crow's Feet (Periorbital)

Inject 6-12 U per side intradermally or just deep to orbicularis oculi, spacing injections ~1 cm. Stay ~1 cm lateral to the orbital rim to reduce risk of diplopia. For skin-quality concerns, favour micro-droplet patterns and review at 2 weeks for fine-tuning rather than high initial doses. ^{1 2}

Brow Lift / Lateral Tail

Micro-dosing 0.5-1 U per point at the lateral orbicularis/frontails interplay can subtly elevate the tail without over-inhibiting frontalis lateral fibers. Keep injections superficial and assess baseline brow asymmetry; overtreatment can cause lateral brow drop. ^{1 2}

Masseter

Jawline slimming or bruxism: 25-40 U per side in 3-4 deep intramuscular points. Palpate clench to map the bulk. Keep injections within masseter boundaries to avoid diffusion to zygomaticus or risorius; avoid parotid duct course. Reassess function and symmetry at 6-10 weeks. ^{1 2 6}

Chin (Mentalis)

Total 2-6 U split across two central intramuscular points to reduce pebbling and hyperactivity. Map the mentalis footprint; avoid diffusion that can flatten chin shape. Document pre/post dynamic photos to calibrate retreatment intervals. ^{1 2}

DAO / Marionette

2-4 U per side, placed ~1 cm lateral to the oral commissure at mandibular border to reduce downward pull. Avoid diffusion into depressor labii inferioris (DLI) to prevent smile asymmetry. Start low, reassess at 2 weeks, and escalate cautiously. ^{1 2}

Platysmal Bands (Neck)

Inject 1-2 U per band per site, 4-6 sites per side, superficial plane. Counsel about transient neck weakness or dysphagia risk if overdosed or mis-placed. Consider staged treatment with review for dose titration. ^{1 7}

Dermal Filler - Tear Trough

0.1-0.3 mL per side using a cannula in the pre-periosteal or deep-suborbicularis plane with low G' HA. Avoid medial boluses; use micro-threads from lateral entry and pause to assess perfusion and edema tendency. Defer if fluid-dominant or severe malar edema risk. ^{2 3 7}

Dermal Filler - Midface

Deep supraperiosteal boluses (0.3-0.6 mL each) over zygomatic eminence with high G' HA for skeletal support. In the medial cheek, favour a 25 G cannula in the deep fat plane with micro-aliquots to minimise injury to the infraorbital bundle. Avoid boluses near the nasojugal fold. ^{2 7 8}

Dermal Filler - Lips

Total 0.5-1.0 mL using low G', high-cohesivity HA in submucosal plane. Use micro-threads and avoid intravascular injection by low pressure, slow rate, and frequent tissue blanch checks. For philtral shaping, minimal columns with careful symmetry checks. ^{2 5}

Dermal Filler - Chin & Jawline

0.5-1.0 mL per point in deep supraperiosteal plane with high G' HA for projection and definition. Stay lateral to the facial artery path and away from the mental foramen. Layer vertically and reassess angle and pogonion from oblique views before adding volume. ^{2 8}

Note: Doses/volumes are indicative and must be individualised based on anatomy, sex, muscle strength, prior treatments, and risk assessment. Escalate per vascular occlusion/anaphylaxis protocols where indicated.

Sources

1. AHPRA (2025), Guidelines for cosmetic procedures., viewed 28 October 2025, https://www.ahpra.gov.au/Resources/Cosmetic-surgery-hub/Cosmetic-procedure-guidelines.aspx ↩
2. ACE Group World, Complications & injection safety., viewed 28 October 2025, https://uk.acegroup.online/ ↩
3. Beleznay K. et al., Blindness after filler injection. Plast Reconstr Surg (2015)., viewed 28 October 2025, https://journals.lww.com/plasreconsurg/Fulltext/2015/12000/Blindness_After_Facial_Filler_Injections__A.41.aspx ↩
4. Australian Resuscitation Council (ARC), Anaphylaxis/BLS., viewed 28 October 2025, https://resus.org.au/guidelines/ ↩
5. Goodman GJ et al., Vascular compromise consensus. Plast Reconstr Surg., viewed 28 October 2025, https://journals.lww.com/plasreconsurg/pages/default.aspx ↩
6. RACGP, Cosmetic/procedural resources., viewed 28 October 2025, https://www.racgp.org.au/clinical-resources/clinical-guidelines ↩
7. Anatomy/safety in high-risk zones (review)., viewed 28 October 2025, https://doi.org/10.1097/PRS.0000000000001884 ↩
8. Facial artery/temporal region variation (review)., viewed 28 October 2025, https://doi.org/10.1093/asj/sjw123 ↩